A breakdown of how Direct Meds prices its GLP-1 program, including the subscription structure and what drives the monthly total. It explains the cash-pay and branded-versus-compounded split, references the April 2026 telehealth market range, and describes the one cost input no quote includes: your baseline genetics.

Direct Meds Review is a platform helping patients evaluate online GLP-1 providers by assessing credentials, safety standards, and personalization frameworks. Understanding these criteria supports informed decisions about compounded peptide options and provider selection.

How a telehealth program like Direct Meds prices its subscription: the fee, medication, and dispensing components, why compounded-versus-branded is the biggest cost driver, where the real number lives, and the FTO genetics behind trial-and-error. PlexusDx is not affiliated with Direct Meds.

Ro and Direct Meds approach GLP-1 weight management from slightly different angles, one a broad subscription platform and one a compounded-pharmacy service. This independent review contrasts their models, their shared pharmacology, and the inherited metabolic factor neither program measures first.

A balanced review of whether Direct Meds is a legitimate GLP-1 telehealth operator. It examines licensed clinicians, the 503A compounding pathway, clinical oversight, and pricing transparency as verifiable trust signals, then explains the genetic context that sits outside any telehealth program and why it still matters to you.

This review explains how Direct Meds handles tirzepatide, from its GIP/GLP-1 dual-agonist mechanism to the branded-versus-compounded 503A dispensing routes. It covers how evaluation and follow-up work, the SURMOUNT trial evidence, the typical monthly cost range, and the genetic terrain the compound ultimately acts on within your body.